BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Padmanabhan P, Desikan R, Dixit NM. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. Nat Comput Sci 2022;2:123-31. [DOI: 10.1038/s43588-022-00198-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Tatematsu D, Akao M, Park H, Iwami S, Ejima K, Iwanami S. Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors. J Theor Biol 2023;561:111403. [PMID: 36586664 DOI: 10.1016/j.jtbi.2022.111403] [Reference Citation Analysis]
2 Gazeau S, Deng X, Ooi HK, Mostefai F, Hussin J, Heffernan J, Jenner AL, Craig M. The race to understand immunopathology in COVID-19: perspectives on the impact of quantitative approaches to understand within-host interactions. Immunoinformatics (Amst) 2023;:100021. [PMID: 36643886 DOI: 10.1016/j.immuno.2023.100021] [Reference Citation Analysis]
3 Korosec CS, Farhang-Sardroodi S, Dick DW, Gholami S, Ghaemi MS, Moyles IR, Craig M, Ooi HK, Heffernan JM. Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. Sci Rep 2022;12:21232. [PMID: 36481777 DOI: 10.1038/s41598-022-25134-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yang B, Huang X, Gao H, Leung NH, Tsang TK, Cowling BJ. Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. BMC Med 2022;20:409. [PMID: 36284331 DOI: 10.1186/s12916-022-02600-0] [Reference Citation Analysis]
5 Stolfi P, Castiglione F, Mastrostefano E, Di Biase I, Di Biase S, Palmieri G, Prisco A. In-silico evaluation of adenoviral COVID-19 vaccination protocols: Assessment of immunological memory up to 6 months after the third dose. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.998262] [Reference Citation Analysis]
6 Pires De Souza GA, Le Bideau M, Boschi C, Wurtz N, Colson P, Aherfi S, Devaux C, La Scola B. Choosing a cellular model to study SARS-CoV-2. Front Cell Infect Microbiol 2022;12:1003608. [DOI: 10.3389/fcimb.2022.1003608] [Reference Citation Analysis]
7 Hernandez-Suarez C, Murillo-Zamora E. Waning immunity to SARS-CoV-2 following vaccination or infection. Front Med (Lausanne) 2022;9:972083. [PMID: 36313998 DOI: 10.3389/fmed.2022.972083] [Reference Citation Analysis]
8 Desikan R, Linderman SL, Davis C, Zarnitsyna VI, Ahmed H, Antia R. Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity. Front Immunol 2022;13:985478. [DOI: 10.3389/fimmu.2022.985478] [Reference Citation Analysis]
9 Kandala B, Plock N, Chawla A, Largajolli A, Robey S, Watson K, Thatavarti R, Dubey SA, Cheung SA, de Greef R, Stone J, Sachs JR. Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. eBioMedicine 2022;84:104264. [DOI: 10.1016/j.ebiom.2022.104264] [Reference Citation Analysis]
10 Voutouri C, Hardin CC, Naranbhai V, Nikmaneshi MR, Khandekar MJ, Gainor JF, Stylianopoulos T, Munn LL, Jain RK. Mechanistic model for booster doses effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-CoV-2.. [DOI: 10.1101/2022.06.30.22277076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chatterjee B, Singh Sandhu H, Dixit NM. Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms. PLoS Pathog 2022;18:e1010630. [DOI: 10.1371/journal.ppat.1010630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Morajkar RV, Kumar AS, Kunkalekar RK, Vernekar AA. Advances in nanotechnology application in biosafety materials: a crucial response to COVID-19 pandemic. Biosaf Health 2022. [PMID: 35765656 DOI: 10.1016/j.bsheal.2022.06.001] [Reference Citation Analysis]
13 Desikan R, Linderman SL, Davis C, Zarnitsyna V, Ahmed H, Antia R. Modeling suggests that multiple immunizations or infections will reveal the benefits of updating SARS-CoV-2 vaccines.. [DOI: 10.1101/2022.05.21.492928] [Reference Citation Analysis]
14 . Mathematical model predicts efficacy of COVID-19 vaccines. Nat India 2022. [DOI: 10.1038/d44151-022-00030-8] [Reference Citation Analysis]
15 Schiffer JT. Correlates of protection via modeling. Nat Comput Sci 2022;2:140-141. [DOI: 10.1038/s43588-022-00221-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Padmanabhan P, Dixit NM. Modelling how the altered usage of cell entry pathways by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors.. [DOI: 10.1101/2022.01.13.476267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]